QIAGEN NV, Hilden, Germany, offers new insights into its next-generation sequencing (NGS) initiative, recently unveiling a sample-to-result NGS workflow at the Advances in Genome Biology and Technology (AGBT) meeting, which are designed to enable the routine use of this breakthrough technology beyond life sciences research in clinical diagnostics.
|Peer M. Schatz|
"We are pleased with the progress of our NGS initiative to create a complete portfolio of products and services to make this breakthrough technology more effective, robust, and scalable for areas such as clinical research and diagnostics," says Peer M. Schatz, CEO, QIAGEN. "The development of our complete sample-to-result workflow is a key achievement in our initiative to offer a seamless integration of new NGS platforms with high-quality reagents, molecular testing content, and services."
Dietrich Hauffe, PhD, senior vice president, life sciences business area, says the company is planning to begin placing NGS workflows with selected customer groups during 2013 and expects NGS to complement established molecular technologies, particularly real-time PCR.
The company's automated NGS workflow offers a streamlined and automated workflow built on components that include the following:
Click here to learn more.